Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly & Co.

www.lilly.com

Latest From Eli Lilly & Co.

Coronavirus Update: Gilead Ready To Unveil Remdesivir Price

Gilead is preparing to unveil its long-term commercial plan for the antiviral therapy, including its expectations on prices and profits.

Coronavirus COVID-19 Companies

Bristol Wins First Of Two Important Opdivo/Yervoy First-Line NSCLC Approvals

Data from CheckMate-9LA and -227 that will be presented at the ASCO virtual meeting support a low-dose chemo combo with the two drugs and the newly US FDA-approved chemo-free indication. 

Approvals ASCO

Hanmi In Tough Spot After Sanofi Efpeglenatide U-Turn

Sanofi’s decision to return to originator Hanmi all rights to the novel diabetes candidate efpeglenatide, which is in global Phase III trials, has placed the South Korean pharma in a difficult spot. Unless there are some surprisingly positive data, finding a major global partner for commercialization may be tough.

South Korea Deals

Gedeon Richter Chief Makes Biosimilars Prophecy

Gedeon Richter has high ambitions for biosimilars, recently penning a deal to bring in a tocilizumab biosimilar that is currently under development. During its first-quarter earnings call, the Hungarian company’s CEO gave his current thinking on how payers may treat biosimilars amidst the COVID-19 pandemic.

Biosimilars Coronavirus COVID-19
See All

Company Information

UsernamePublicRestriction

Register